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ABSTRACT - The aim of this study was to assess bone mineral density and vitamin D metabolism in patients on
chronic anticonvulsant therapy. Methods: Sixty-nine men, outpatients on chronic anticonvulsant therapy, who had
been treated for at least 5 years, were studied, comparing them to thirty healthy controls. Bone mineral density was
measured as well as serum levels of calcium, ionized calcium, alkaline phosphatase, PTH, 25-hydroxycholecalciferol
and 1,25-dihydroxycholecalciferol. Results: No differences in bone mineral density, serum levels of vitamin D and
intact-PTH were observed between patients and controls. Bone mineral density was not associated with chronic
anticonvulsant therapy. Conclusion: Those adult patients who were on chronic anticonvulsant therapy and who
lived in low latitude regions had normal bone mineral density as well as vitamin D serum levels.
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Densidade mineral óssea, vitamina D e terapia anticonvulsivante
RESUMO - O objetivo deste estudo foi avaliar a densidade mineral óssea e o metabolismo da vitamina D em
usuários crônicos de anticonvulsivantes. Métodos: Foram estudados 69 pacientes ambulatoriais, masculinos,
usuários crônicos de anticonvulsivantes por período mínimo de 5 anos e comparados a 30 controles normais.
Foram efetuadas as medidas da densidade mineral óssea e dos níveis plasmáticos do cálcio, cálcio iônico, fosfatase
alcalina, paratormônio, 25-hidroxi-colecalciferol e 1,25-di-hidroxi-colecalciferol. Resultados: Nenhuma diferença
na densidade mineral óssea e nos níveis plasmáticos da vitamina D e paratormônio foram observadas entre os
pacientes e os controles. A densidade mineral óssea não se mostrou associada ao uso crônico de anticonvulsivantes.
Conclusões: Pacientes adultos, do sexo masculino, usuários crônicos de anticonvulsivantes, residentes em regiões
ensolaradas, têm densidade mineral óssea e níveis plasmáticos de vitamina D normais.
PALAVRAS-CHAVE: vitamina D, cálcio, anticonvulsivante, densidade mineral óssea.
Alterations in calcium, vitamin D and bone tissue metabolism have been associated with the
following drugs: phenobarbital, phenytoin, primidone and carbamazepine1,2. Alterations in the
metabolism of calcium are generally very slight and subclinical, but clear cases of hypocalcemia
could occur in 4% to 30% of individuals. The intensity of the clinical symptoms depends on many
factors, such as: intake of vitamin D, exposure to the sun, physical activity, other diseases that
interfere in vitamin D metabolism, the positive correlation of these manifestations with the type of
drug, individual drug dosage, and period of exposure, as well as polytherapy3,6.
This study, which was conducted to assess bone mineral density and vitamin D metabolism in
a sample of the Brazilian epileptic population on chronic anticonvulsant therapy, was motivated by
the fact that the intensity of alterations of vitamin D metabolism and bone mass was related not only
to the chronic use of anticonvulsants but also to other variables. These included the characteristics
of the population, such as sunlight exposure.
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METHOD
Sixty-nine epileptic men, outpatients at the Sector for Epilepsy, Department of Neurology, UNICAMP,
were retrospectively evaluated.
The mean age of these patients was 37.6 years (SD = 10.92), all being on single or combined anticonvulsant
therapy consisting of phenobarbital, phenytoin and carbamazepine for at least a period of 5 years (Table 1 and
Table 2). The patients were kept on single or combined anticonvulsant therapy with the same drug for an average
period of 10.33 years (SD = 5.54).
The control group consisted of 30 healthy men and the mean age was 34.6 years (SD=9.26). The exclusion
criterion used was: antecedents or the presence of diseases that could cause alterations in the metabolism of
calcium and vitamin D. All the participants were from a 20 to 24 degree south latitude region and had similar
mean weight and height.
The serum levels of calcium, ionized calcium, alkaline phosphatase, albumin, PTH, 25-
hydroxycholecalciferol and 1,25 dihydroxycholecalciferol were measured. Radioimmunoassay was used to
measure the intact-PTH molecule (NIKOLS, USA) and it was also used to measure 25-hydroxy-vitamin D and
1,25-dihydroxy-vitamin D (interassay coefficient of variation was 14.96 and 18.93 respectively and intra-assay
coefficient of variation was 11.08 and 12.13 respectively – INCSTAR (USA).
LUNAR – DEXA equipment with double emission X-rays (DPX) was used to measure bone mineral
density (BMD) in the lumbar region of the spine and in the femoral neck (CV =2%).
For the comparison of independent variables, Student t test or Mann-Whitney U test was used, where
appropriate. Multiple regression analysis was carried out to verify the relationship between bone mineral density
and the use of anticonvulsant therapy, duration of the therapy, body mass index, age, serum levels of calcium,
ionized calcium, alkaline phosphatase and albumin. Statistical analysis was done by SAS statistic package. For
the comparison of bone mineral density between the different anticonvulsants drug treatments, Kruskal-Wallis
and Student t tests were used. For all statistical tests, significance was defined as p<0.05.
Table 1. Patients according to the therapy used.
Therapeutic scheme Number Percentage %
Carbamazepine 35 50
Phenytoin 12 17
Phenobarbital 11 16
Phenobarbital+Carbamazepine 5 7
Phenytoin+Carbamazepine 2 3
Phenobarbital+Phenytoin 3 5
Phenobarbital+Phenytoin+Carbamazepine 1 2
Table 2. Patients according to the anticonvulsant therapy and the dosage used in single or
combined therapy for at least 5 years.
Dose (mg/dia)
Anticonvulsant Number  Mean SD
Phenobarbital 17 123.33 56.27
Phenytoin 16 334.37 110.63
Carbamazepine 39 1072.0 388.48
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RESULTS
Anticonvulsant chronic users did not show a reduction in BMD (Table 3).
The mean serum levels of vitamin D and PTH, observed in the patients, were the same as those
of the control group. The mean serum calcium levels were lower and the mean serum phosphatase
alkaline and albumin levels were higher in the anticonvulsant users than in the controls (Table 4).
Bone mineral density was not influenced by anticonvulsant therapy, period of treatment, body
mass index, serum levels of calcium, alkaline phosphatase, albumin and ionized calcium (Table5).
Table 3. Bone mineral density results of the patients in comparison with the control group.
Bone mineral density (g/cm2)
patient (n=69) control (n=28)
mean SD mean SD p
Spine (L2-L4) 1.181 0.127 1.215 0.147 0.252
Femoral neck 1.043 0.122 1.052 0.178 0.782
Table 4. Comparing laboratory exams.
Variable Patients Control
n mean SD n mean SD p*
PTH (pg/ml) 27 22.796 12.949 15 25.133 11.073 0.869
25(OH)VITD (ng/ml) 29 32.010 10.336 25 33.160 10.501 0.211
1,25 (OH)2VITD (pg/ml) 28 27.271 10.264 23 24.192 8.787 0.462
Calcium (mg/dl) 68 8.978 0.466 30 9.263 0.503 0.008*
Alkaline phosphatase (UI) 59 216.156 69.14 30 171.833 42.764 0.001*
Albumin (g/dl) 64 4.173 0.440 30 3.838 0.371 0.0002*
*p<0.05
Table 5. Evaluation of the relationship between bone mineral density and the use of anticonvulsant therapy, body
mass index, age, duration of the therapy, calcium, ionized calcium, alkaline phosphatase and albumin.
Variable Bone mineral density Bone mineral density
(Spine) (Femoral neck)
Parameter estimate p Parameter estimate p
Intercep  1.195 0.013 1.337 0.002
Anticonvulsant therapy  -0.034 0.407 -0.046 0.753
Body mass index  -0.001 0.843  0.007 0.089
Age  -0.002 0.407  -0.006 0.016
Duration of the therapy  0.000 0.883  0.001 0.753
Calcium  0.018 0.617  -0.012 0.714
Alkaline Phosphatase  0.000 0.914  -0.000 0.768
Albumin  0.012 0.802  -0.007 0.870
Ionized calcium  -0.076 0.761  -0.098 0.662
R2  0.062  0.181
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Bone mineral density in spine and femoral neck was not influenced by the kind of
anticonvulsant used (p=0.729 and p=0.824, respectively) or by single or combined-drug therapy
(p=0.240 and p=0.653, respectively).
DISCUSSION
Bone mineral density was not decreased and vitamin D serum levels were normal in the
population studied. There are some risk factors that induce alterations in vitamin D metabolism and
bone disease in chronic anticonvulsant users.
 These patients were at low risk for these abnormalities because of the following reasons:
First, the population in this study consisted of outpatients that had routine physical outdoor activity.
Second, as long as the exposure to sunlight is adequate, the most important source of vitamin D is
endogenous3. The skin synthesis of vitamin D depends on the intensity of sunlight and the quantity
of ultra-violet rays that reach the earth and these are inversely related to latitude7. The production of
vitamin D, by the skin, varies according to the season in regions that have greater latitude and
production is less during autumn/winter. In these regions, exogenous sources of vitamin D are very
important to maintain the daily vitamin needs of the normal population8 and especially in the case of
anticonvulsant users, where the necessity for this vitamin is greater, because the hepatic enzyme
system activity increases the catabolism of this vitamin into inactive products1,5. Phenobarbital,
phenytoin, primidone and carbamazepine increase the hepatic microsomal enzyme activity which
accelerates the hydroxylation of vitamin D, as well as the catabolism of vitamin D from 25-
hydroxycholecalciferol and 1,25-dihydroxycholecalciferol into inactive products leading to a
reduction in vitamin reserves and increasing daily needs9. It could be presumed that the patients in
this study had an adequate synthesis of vitamin D as they came from a region situated between a
latitude 20 to 24 degrees and were exposed to right sunlight throughout the year. This asumption
was confirmed by the fact that they had the same levels of 25 (OH)VITD as the control group. This
indicated the possibility that the endogenous synthesis of vitamin D in young adults of this region
met the hormonal needs that had been increased by the anticonvulsants. And finally, the predominant
therapy schedule was monotherapy (83%), which produces less alterations in bone mass, than
polytherapy does3.
The mean serum levels of calcium, found in the patients, were less than those in the control
group. These results confirm those found in literature, showing the mean reduction in calcium serum
levels as 0.3-0.8mg/dl3. In the present study however, the reduction found was 0.3mg/dl, which is
the lower limit of this variation and was not enough to increase the PTH serum levels and was not
associated with the metabolism of vitamin D. This reduction in the calcium serum levels could be
attributed to the direct action of the anticonvulsants in the cells (intestine and bone) as shown in the
case of phenobarbital and phenytoin but this has not yet been proven. However, in the case of
carbamazepine, this asumption was in agreement with normal levels of serum 25-hydroxycho-
lecalciferol that were found3,10,11.
The mean total alkaline phosphatase serum levels were significantly higher in the patients
than in the control group. Richens & Rowe5 measured the serum levels of alkaline phosphatase
isoenzymes in chronic anticonvulsant users and found that the hepatic fraction was predominant
(60%). This result was similar to the one obtained by Hahn et al.6, which showed an increase in the
hepatic isoenzyme in recent anticonvulsant users (up to six months). This increase in hepatic alkaline
phosphatase serum, which may alter hepatic function, could be due to the chronic use of anticonvulsant
medication12. Besides finding an increase in alkaline phosphatase, Weinstein et al.13 found increased
serum levels of gamma-glutamil-transferase in 88% of chronic anticonvulsant users. Therefore, the
increased alkaline phosphatase levels found in this present study were probably due mainly to hepatic
isoenzyme. This hypothesis is strengthened by the fact that vitamin D serum levels found in patients
were similar to those of the control group.
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Conclusions
The results of this study conclude that in a sample of Brazilian epileptic adult outpatients
living in a region situated below 24 degrees latitude, with very intense sunlight exposure throughout
the year, chronic anticonvulsant treatment was not associated to alterations of bone mineral density
and vitamin D metabolism. However, other studies, carried out in a low latitude region, with epileptic
patients on chronic anticonvulsant therapy presenting therefore great risk for bone disease, are
necessary to show all the impact of anticonvulsant medication on the metabolism of calcium and
bone mineral density.
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